European Court Opens Door for Stem Cell Patenting
By GEN,
Genetic Engineering & Biotechnology News
| 12. 18. 2014
Today the European Court of Justice (CJEU) ruled that human embryonic stem cell patents could be allowed if organisms can't develop into human being. The decision overturns a 2011 European Union ruling that outlawed patents on hESC research, affirming that pluripotent human stem cells derived from parthoenogenetically activated oocytes can be patented in Europe.
Parthenogenesis refers to the initiation of embryogenesis without fertilization by oocyte activation in the absence of sperm though a variety of chemical and electrical techniques. The activated oocyte contains a single or double set of maternally derived chromosomes but does not contain paternal DNA.
While patents on hESC have been upheld in the United States, the European Patent Office (EPO) has refused to grant many of the same patents on ethical grounds if the commercial exploitation of those patents goes against public order or morality. Combined with a principle of noncommercialization of the human embryo, human body, and its products led Europe to deny the patentability of hESC.
Today’s judgment was precipitated though an appeal brought by International Stem Cell Corporation (ISC), a California-based biotechnology company...
Related Articles
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Alice Park, TIME | 07.08.2025
Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth.
To date, there haven’t been many reliable treatment options for these babies. The few that do exist involve...
